Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

In $4.9B Alpine deal, Vertex sees best-in-class therapy with room for label expansions

Buyer believes povetacicept can outshine others in BAFF/APRIL class, even if not first to market — and can become a pipeline-in-a-product

April 12, 2024 1:44 AM UTC

Vertex’s $4.9 billion acquisition of Alpine hinges on its belief that it is obtaining a mid-stage program that will turn out to be the best in an emerging class of BAFF/APRIL inhibitors to treat IgA nephropathy, and perhaps other immunologic diseases.

The decision by Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) to buy Alpine Immune Sciences Inc. (NASDAQ:ALPN) for $65 per share will add povetacicept to its pipeline ahead of a Phase III trial due to begin next half, augmenting a growing kidney disease franchise that could help diversify Vertex’s business beyond its strong-selling cystic fibrosis drugs...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article